460 Stock Overview
An investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Sihuan Pharmaceutical Holdings Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.66 |
| 52 Week High | HK$1.02 |
| 52 Week Low | HK$0.49 |
| Beta | 0.58 |
| 1 Month Change | -5.71% |
| 3 Month Change | -2.94% |
| 1 Year Change | 3.13% |
| 3 Year Change | -55.70% |
| 5 Year Change | -26.67% |
| Change since IPO | -77.12% |
Recent News & Updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Recent updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Shareholder Returns
| 460 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.5% | -0.9% | 0.3% |
| 1Y | 3.1% | -7.7% | 19.4% |
Return vs Industry: 460 exceeded the Hong Kong Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: 460 underperformed the Hong Kong Market which returned 19.1% over the past year.
Price Volatility
| 460 volatility | |
|---|---|
| 460 Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in HK Market | 17.7% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 460 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 460's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,648 | Weicheng Guo | www.sihuanpharm.com |
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. The company operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. It offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions.
Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary
| 460 fundamental statistics | |
|---|---|
| Market cap | HK$6.14b |
| Earnings (TTM) | -HK$40.23m |
| Revenue (TTM) | HK$1.87b |
3.3x
P/S Ratio-152.8x
P/E RatioIs 460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 460 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.75b |
| Cost of Revenue | CN¥598.10m |
| Gross Profit | CN¥1.16b |
| Other Expenses | CN¥1.19b |
| Earnings | -CN¥37.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 65.91% |
| Net Profit Margin | -2.15% |
| Debt/Equity Ratio | 21.4% |
How did 460 perform over the long term?
See historical performance and comparisonDividends
6.1%
Current Dividend Yield-467%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 01:50 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Harry He | China Galaxy International Securities (Hong Kong) |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |